MX2010001745A - Imidazoles fusionados para el tratamiento del cancer. - Google Patents

Imidazoles fusionados para el tratamiento del cancer.

Info

Publication number
MX2010001745A
MX2010001745A MX2010001745A MX2010001745A MX2010001745A MX 2010001745 A MX2010001745 A MX 2010001745A MX 2010001745 A MX2010001745 A MX 2010001745A MX 2010001745 A MX2010001745 A MX 2010001745A MX 2010001745 A MX2010001745 A MX 2010001745A
Authority
MX
Mexico
Prior art keywords
cancer treatment
fused imidazoles
fused
imidazoles
pi3k
Prior art date
Application number
MX2010001745A
Other languages
English (en)
Inventor
Thomas Maier
Thomas Beckers
Thomas Baer
Astrid Zimmermann
Swen Hoelder
Volker Gakeler
Hemant Joshi
Yogesh S Munot
Umesh Bhise
Sunil Chavan
Sachin S Shivatare
Sarvesh A Patel
Vikas Gore
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07118733A external-priority patent/EP2062893A1/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2010001745A publication Critical patent/MX2010001745A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos de fórmula (I) (ver fórmula I) tautórneros o estereoisómeros de éstos, o sus sales, donde el anillo B y el imidazol al que está fusionado, R4, R6, y R7 tienen los significados indicados en la descripción y las reivindicaciones, que son inhibidores eficaces de la vía Pi3K/Akt.
MX2010001745A 2007-08-14 2008-08-14 Imidazoles fusionados para el tratamiento del cancer. MX2010001745A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1573MU2007 2007-08-14
EP07118733A EP2062893A1 (en) 2007-10-18 2007-10-18 Fused imidazoles for cancer treatment
PCT/EP2008/060686 WO2009021990A1 (en) 2007-08-14 2008-08-14 Fused imidazoles for cancer treatment

Publications (1)

Publication Number Publication Date
MX2010001745A true MX2010001745A (es) 2010-03-10

Family

ID=39876840

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001745A MX2010001745A (es) 2007-08-14 2008-08-14 Imidazoles fusionados para el tratamiento del cancer.

Country Status (24)

Country Link
US (2) US8592591B2 (es)
EP (1) EP2176259B1 (es)
JP (1) JP5327652B2 (es)
KR (1) KR20100049589A (es)
CN (1) CN101835776A (es)
AR (1) AR067946A1 (es)
AT (1) ATE503757T1 (es)
AU (1) AU2008288390A1 (es)
CA (1) CA2695251C (es)
CL (1) CL2008002397A1 (es)
CR (1) CR11271A (es)
DE (1) DE602008005894D1 (es)
DO (1) DOP2010000057A (es)
EA (1) EA201000297A1 (es)
EC (1) ECSP109965A (es)
MA (1) MA31609B1 (es)
MX (1) MX2010001745A (es)
PA (1) PA8793301A1 (es)
PE (1) PE20090596A1 (es)
SV (1) SV2010003482A (es)
TN (1) TN2010000071A1 (es)
TW (1) TW200924761A (es)
UY (1) UY31292A1 (es)
WO (1) WO2009021990A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ576570A (en) * 2006-10-19 2010-11-26 Takeda Pharmaceutical 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
PA8793301A1 (es) * 2007-08-14 2009-04-23 Bayer Schering Pharma Ag Imidazoles bicíclicos fusionados
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
EP2396331B1 (en) * 2009-02-13 2013-10-16 Bayer Intellectual Property GmbH Fused pyrimidines as akt inhibitors
AU2010226490A1 (en) 2009-03-20 2011-10-06 Amgen Inc. Inhibitors of PI3 kinase
TW201103943A (en) 2009-04-27 2011-02-01 Shionogi & Co Urea derivative having pi3k inhibitory activity
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
NZ599597A (en) 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
WO2011053476A1 (en) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CN103097384B (zh) * 2010-07-12 2017-02-15 拜耳知识产权有限责任公司 取代的咪唑并[1,2‑a]嘧啶和吡啶
CN103384670B (zh) 2010-07-28 2016-05-25 拜耳知识产权有限责任公司 取代的咪唑并[1,2-b]哒嗪
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
PL2698372T3 (pl) * 2011-04-06 2016-07-29 Taiho Pharmaceutical Co Ltd Nowy związek imidazooksazynowy lub jego sól
JO3068B1 (ar) * 2011-04-07 2017-03-15 Bayer Ip Gmbh إيميدازوبيريميدينات كمثبطات كيناز akt
MX344600B (es) 2011-06-27 2016-12-20 Janssen Pharmaceutica Nv Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina.
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
US9260435B2 (en) * 2012-01-10 2016-02-16 Bayer Pharma Aktiengesellschaft Substituted imidazopyrazines as Akt kinase inhibitors
CN104066736B (zh) 2012-01-10 2017-03-08 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的吡唑并嘧啶
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
JP5855250B2 (ja) * 2012-07-02 2016-02-09 大鵬薬品工業株式会社 イミダゾオキサジン化合物による抗腫瘍効果増強剤
RU2667058C2 (ru) 2012-07-09 2018-09-14 Янссен Фармацевтика Нв Ингибиторы фермента фосфодиэстеразы 10
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2016136928A1 (ja) 2015-02-27 2016-09-01 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2018081167A1 (en) * 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908929B2 (en) 2000-03-31 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
EP1277754B8 (en) * 2000-04-27 2005-09-28 Astellas Pharma Inc. Imidazopyridine derivatives
WO2004096131A2 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
EA009038B1 (ru) * 2003-07-30 2007-10-26 Лабораториос С.А.Л.В.А.Т., С.А. Замещенные имидазопиримидины для предупреждения и лечения рака
DE602005026509D1 (de) 2004-04-09 2011-04-07 Merck Sharp & Dohme Hemmer der akt aktivität
WO2006036395A2 (en) * 2004-08-23 2006-04-06 Merck & Co., Inc. Inhibitors of akt activity
CA2589084A1 (en) * 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
BRPI0610863A2 (pt) * 2005-05-20 2010-08-03 Array Biopharma Inc compostos inibidores de raf e métodos para sua utilização
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
TW200800213A (en) * 2005-09-02 2008-01-01 Abbott Lab Novel imidazo based heterocycles
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
PA8793301A1 (es) * 2007-08-14 2009-04-23 Bayer Schering Pharma Ag Imidazoles bicíclicos fusionados

Also Published As

Publication number Publication date
PE20090596A1 (es) 2009-06-07
CL2008002397A1 (es) 2009-09-25
EA201000297A1 (ru) 2010-08-30
TN2010000071A1 (en) 2011-09-26
AU2008288390A1 (en) 2009-02-19
DOP2010000057A (es) 2010-04-15
US9387204B2 (en) 2016-07-12
MA31609B1 (fr) 2010-08-02
JP2010535847A (ja) 2010-11-25
CA2695251A1 (en) 2009-02-19
US8592591B2 (en) 2013-11-26
CR11271A (es) 2010-05-19
EP2176259B1 (en) 2011-03-30
KR20100049589A (ko) 2010-05-12
CN101835776A (zh) 2010-09-15
US20140088110A1 (en) 2014-03-27
AR067946A1 (es) 2009-10-28
DE602008005894D1 (de) 2011-05-12
JP5327652B2 (ja) 2013-10-30
PA8793301A1 (es) 2009-04-23
CA2695251C (en) 2016-06-21
ECSP109965A (es) 2010-03-31
SV2010003482A (es) 2010-07-06
EP2176259A1 (en) 2010-04-21
UY31292A1 (es) 2009-03-31
ATE503757T1 (de) 2011-04-15
US20090156604A1 (en) 2009-06-18
WO2009021990A1 (en) 2009-02-19
TW200924761A (en) 2009-06-16

Similar Documents

Publication Publication Date Title
MX2010001745A (es) Imidazoles fusionados para el tratamiento del cancer.
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
MX2010003368A (es) Derivados de imidazol.
NZ603155A (en) Phospholipid drug analogs
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
MY184101A (en) Indoles
NZ596488A (en) 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
IN2012DN02081A (es)
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
TN2012000401A1 (en) Heterocyclic compound
NZ597517A (en) 5-fluoropyrimidinone derivatives
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
MY176944A (en) Substituted pyrimidines for the treatment of diseases such as cancer
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
GEP20146138B (en) Method for treating androgen receptor positive cancers
TN2011000404A1 (en) Fused pyrimidines
TN2010000070A1 (en) Fused bicyclic pyrimidines
MY166026A (en) Tetrahydro-pyrido-pyrimidine derivatives
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
CL2008001074A1 (es) Uso de compuestos de triazol, antagonistas de smo para tratar cancer.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
WO2012078757A3 (en) Combination for breast cancer therapy with hsp90 inhibitory compounds

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal